TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects
Key facts
- Who runs it
- University Medical Center Groningen
- Where
- Netherlands3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 939 people enrolled
- Started
- Jul 2014
- Ended
- Apr 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Vena punction
- Record updated
- 15 September 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who cannot take part
- Mental disorder (no informed consent available)
- Presence of active malignant disease
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
Other criteria
- All participating patients have to meet the following criteria:
- Alive
- TC diagnosis between 01-01-1976 to 31-12-2007
- TC treatment center: UMCG, NKI/AVL, Erasmus MC, UMCN, LUMC
- Younger than 50 years of age at TC diagnosis
- Written informed consent; Cases have to fulfill, beside the aforementioned criteria, the following criteria:
- Diagnosed with either myocardial infarction (MI), proven coronary artery disease (CAD) (CTCAE-4 grade 2 or higher) or congestive heart failure (CHF) (CTCAE-4 grade 2 or higher)
- No medical history of CVD before diagnosis of TC; In order to be eligible to participate in the cardiometabolic risk inventory study (and to be invited to a study assessment), a subject must meet, next to the criteria mentioned in "1)", the following inclusion criteria:
- Younger than 40 years of age at TC diagnosis
- Younger than 75 years of age at moment of inclusion
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Testicular cancer (TC) is a rare disease, which mostly affects young men aged 15-35 years. Their life expectancy has greatly improved due to the introduction of platinum-containing chemotherapy for disseminated TC in the late 1970s. Given the good prognosis of TC nowadays, prevention or early detection of late adverse effects of TC treatment has become increasingly important. Current literature suggests that TC treatment, and specifically exposure to platinum agents, is associated with increased risk of cardiovascular morbidity and mortality. The precise role of treatment components like platinum in the pathogenesis of cardiometabolic changes and cardiovascular disease (CVD) warrants further investigation, since it is not known if CVD develops through direct platinum-induced damage of the vascular wall or by mediation through development of cardiometabolic riskfactors. The aim of this study is to identify risk factors for development for CVD after treatment for TC. A more profound insight into pathophysiologic mechanisms and identification of risk factors for CVDs is needed to facilitate development of preventive strategies and to optimize survivorship care.
The 2 groups in the trial
- Cases
Patients who developed cardiovascular disease after testicular cancer treatment
Treatment: Vena punction
- Subcohort members
A random selection out of the total cohort of testicular cancer patients per participating hospital
Treatment: Vena punction
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Case-cohort Study to Identify Risk Factors for Cardiovascular Disease in Testicular Cancer Survivors
- Publications
- Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023
- Record updated
- 15 September 2025